Our observations had been unpredicted and, to some extent paradoxical, because all ARV medicines have been developed for subtype B, whichthe antiretroviral medicine tenofovir and abacavir were
We have also investigated the impact of rebound viremia time on the accumulation of drug resistance. It was plausible that subtype B patients could have accumulated far more mutations due…